NEJM appoints Eric Rubin to succeed Jeffrey Drazen as EIC; Amphastar prevails against Momenta/Sandoz in years-long lawsuit
→ The New England Journal of Medicine has selected Eric Rubin as the new editor-in-chief of the Journal and NEJM Group — to replace Jeffrey Drazen, who has been as the EIC of NEJM since 2000. Rubin, who has authored more than 147 scientific articles, has served as an associate editor of the NEJM since 2012 and will start in his new role come September. “Dr. Rubin is a recognized and respected leader in the field of infectious disease, where he is known for his groundbreaking tuberculosis research and his personal dedication to often neglected populations of patients,” said Maryanne Bombaugh, president of the Massachusetts Medical Society, which owns NEJM.
→ Amphastar $AMPH on Wednesday announced the culmination of a protracted patent/antitrust suit related to the launch of enoxaparin — a generic version of Sanofi’s $SNY popular blood thinner Lovenox — in 2012. Momenta Pharmaceuticals $MNTA and Novartis’ Sandoz unit will pay Amphastar $59.9 million no later than July 2, 2019. Momenta/Sandoz made it first to the market with a Lovenox copycat, but despite a legal battle, Amphastar won the right to market its own generic. The settlement will allow Amphastar to collect $59.9 million of the $100 million bond related to compensatory damages stemming from a patent case in which it prevailed in 2017, analysts said.